top of page

  1. van Gulick JJ, Gevers TJ, van Keimpema L, Drenth JP. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: A dichotomy of two ends of a spectrum. Neth J Med. 2011;69(9):367-371. [PubMed].
     

  2. Reed B, McFann K, Kimberling WJ, et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis. 2008;52(6):1042-1050. doi:10.1053/j.ajkd.2008.05.015 [PubMed].
     

  3. Idrizi A, Barbullushi M, Koroshi A, et al. Urinary tract infections in polycystic kidney disease. Med Arch. 2011;65(4):213-215. doi:10.5455/medarh.2011.65.213-215 [PubMed].
     

  4. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470. doi:10.1681/ASN.2018060590 [PubMed].
     

  5. Bennett H, McEwan P, Hamilton K, O'Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: An exploratory analysis using the ADPKD outcomes model. BMC Nephrol. 2019;20(1):136. doi:10.1186/s12882-019-1290-5 [PubMed].
     

  6. Perez Dominguez TS, Rodriguez Perez A, Buset Rios N, et al. Psychonephrology: Psychological aspects in autosomal dominant polycystic kidney disease. Nefrologia. 2011;31(6):716-722. doi:10.3265/Nefrologia.pre2011.Jul.10847 [PubMed].
     

  7. Oberdhan D, Cole JC, Krasa HB, et al. Development of the autosomal dominant polycystic kidney disease impact scale: A new health-related quality-of-life instrument. Am J Kidney Dis. 2018;71(2):225-235. doi:10.1053/j.ajkd.2017.08.020 [PubMed].
     

  8. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(2):101-108. doi:10.1038/nrgastro.2012.254 [PubMed].
     

  9. Takenaka T, Miura S, Kitajima M. The management of polycystic liver disease by tolvaptan. Clin Mol Hepatol. 2020;26(1):70-73. doi:10.3350/cmh.2019.0026 [PubMed].
     

  10. Mizuno H, Sekine A, Suwabe T, et al. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use. PLoS One. 2022;17(2):e0264065. doi:10.1371/journal.pone.0264065 [PubMed].
     

  11. Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018. doi:10.2215/CJN.03960318 [PubMed].
     

  12. Dahl NK, Chebib FT, Rahbari-Oskoui FF, Japes H, Jiang H, Tracy LA, et al. Tolvaptan modifies patient risk class distribution over time in autosomal polycystic kidney disease (ADPKD) an analysis of data from the Tempo 3:4 trial. TH-PO413. Poster presentation at the American Society of Nephrology Kidney Week 2022; November 3, 2022; Orlando, Florida.
     

  13. McGill RL, Saunders MR, Hayward AL, Chapman AB. Health disparities in autosomal dominant polycystic kidney disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022;17(7):976-985. doi:10.2215/CJN.00840122 [PubMed].
     

  14. Murphy EL, Dai F, Blount KL, et al. Revisiting racial differences in ESRD due to ADPKD in the United States. BMC Nephrol. 2019;20(1):55. doi:10.1186/s12882-019-1241-1 [PubMed].
     

  15. Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks: Clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol. 1994;4(9):1670-1674. doi:10.1681/ASN.V491670 [PubMed].
     

  16. Freedman BI, Soucie JM, Chapman A, Krisher J, McClellan WM. Racial variation in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35(1):35-39. doi10.1016/S0272-6386(00)70298-8 [PubMed].
     

  17. Eneanya ND, Yang W, Reese PP. Reconsidering the consequences of using race to estimate kidney function. JAMA. 2019;322(2):113-114. doi:10.1001/jama.2019.5774 [PubMed].
     

  18. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022;79(2):268-288. doi:10.1681/ASN.2021070988 [PubMed].
     

  19. Phakdeekitcharoen B, Treesinchai W, Wibulpolprasert P, Boongird S, Klytrayong P. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: A prospective cohort study. BMC Nephrol. 2021;22(1):178. doi:10.1186/s12882-021-02392-0 [PubMed].
     

  20. Harrison TN, Chen Q, Lee MY, et al. Health disparities in kidney failure among patients with autosomal dominant polycystic kidney disease: A cross-sectional study. Kidney Med. 2023;5(2):100577. doi:10.1016/j.xkme.2022.100577 [PubMed].
     

  21. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: Core curriculum 2016. Am J Kidney Dis. 2016;67(5):792-810. doi:10.1053/j.ajkd.2015.07.037 [PubMed].
     

  22. Mantovani V, Bin S, Graziano C, et al. Gene panel analysis in a large cohort of patients with autosomal dominant polycystic kidney disease allows the identification of 80 potentially causative novel variants and the characterization of a complex genetic architecture in a subset of families. Front Genet. 2020;11:464. doi:10.3389/fgene.2020.00464 [PubMed].
     

  23. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337-348. doi:10.1093/ndt/gfv456 [PubMed].
     

  24. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-172. doi:10.1681/ASN.2013101138 [PubMed].
     

  25. Cornec-Le Gall E, Audrezet MP, Rousseau A, et al. The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942-951. doi:10.1681/ASN.2015010016 [PubMed].
     

  26. Chuang YW, Yu TM, Huang ST, et al. Young-adult polycystic kidney disease is associated with major cardiovascular complications. Int J Environ Res Public Health. 2018;15(5). doi:10.3390/ijerph15050903 [PubMed].
     

  27. Mikolajczyk AE, Te HS, Chapman AB. Gastrointestinal manifestations of autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2017;15(1):17-24. doi:10.1016/j.cgh.2016.06.017 [PubMed].

© 2023 CMEology

bottom of page